Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961683 | 0.79 | CES1 (0.36) | — | |
| SCHEMBL6441444 | 0.77 | CYP3A4 (0.41) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL187040 | 0.75 | TDP2 (0.40) | TDP2NSD2HSP90AA1PAX8CYP1A2 | |
| SCHEMBL258271 | 0.72 | CYP3A4 (0.39) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL13905953 | 0.70 | ACHE (0.38) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL9712600 | 0.69 | ALDH1A1 (0.43) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL9712590 | 0.69 | AR (0.36) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL30394748 | 0.68 | NOTUM (0.37) | TDP2NSD2HSP90AA1PAX8CYP3A4 | |
| SCHEMBL6403160 | 0.68 | CYP3A4 (0.46) | CYP3A4ALOX15TSHR | |
| SCHEMBL1157142 | 0.68 | CYP3A4 (0.46) | CYP3A4CHRM1ALOX15MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544131-B2 | MCL-1 antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190040044-A1 | MCL-1 ANTAGONISTS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-02-07 | — | — | US | disclosed |
| US-10040780-B2 | Mcl-1 antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170066747-A1 | MCL-1 ANTAGONISTS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-03-09 | — | — | US | disclosed |
| WO-2015134539-A1 | MCL-1 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544131-B2 | MCL-1 antagonists | MCL1, BAK1, BCL2L1 | TDP2 3844/4885NSD2 195/4885HSP90AA1 1248/4885 |
| US-10040780-B2 | Mcl-1 antagonists | MCL1, BAK1, BCL3 | TDP2 3563/4885NSD2 236/4885HSP90AA1 1298/4885 |
| US-20170066747-A1 | MCL-1 ANTAGONISTS | MCL1, BAK1, BCL3 | TDP2 3563/4885NSD2 236/4885HSP90AA1 1298/4885 |
| US-20190040044-A1 | MCL-1 ANTAGONISTS | MCL1, BAK1, BCL2L1 | TDP2 3844/4885NSD2 195/4885HSP90AA1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.